[Medical therapy of primitive hypertensive glaucoma-therapeutic principles, perspectives].
The present-day glaucoma therapy is aiming to preserve visual function by decreasing the intraocular pressure below a certain level, that prevents the optic nerve damage to occur. The target IOP must be individualized, considering the IOP level at presentation, the severity of the optic nerve damage, life expectancy and associated risk factors. In order to prevent the glaucoma progression, the more serious the damages are at presentation, the lower the target IOP level must be. New ocular hypotensive agents that have been created during the last few years allowed a more efficient control of the glaucoma progression.
Cucea
R
R
C.M.D.T.A Acad. St. Milcu, Bucuresti.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D018679:Cholinergic Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009883:Ophthalmic Solutions; D011453:Prostaglandins / Q000627:therapeutic use; D016896:Treatment Outcome; D014792:Visual Acuity
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D018679:Cholinergic Agonists; D009883:Ophthalmic Solutions; D011453:Prostaglandins